5 February 2016 - PHARMAC is pleased to announce the approval of an agreement with Novartis New Zealand Ltd. involving filgrastim, used to reduce neutropenia and during mobilisation for allogeneic stem-cell transplant, and methotrexate pre-filled syringes used predominantly for rheumatoid arthritis.

For more details, go to: http://www.pharmac.govt.nz/news/decision-filgrastim-methotrexate-prefilled-syringes/